Abiopharma

News list

Chin Richard 🟡 adjusted position in 0 shares (1 derivative) of Cytek Biosciences, Inc. (CTKB) Filing ID: 022516

Full text

News bot Aug. 20, 2025, 9:43 p.m.
🔍 Chin Richard (Executive)

Company: Cytek Biosciences, Inc. (CTKB)

Report Date: 2025-08-18
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 4,071
- Total shares sold: 4,071
Detailed Transactions and Holdings:
- Acquired 4,071 shares of Common Stock (Direct)
  Date: 2025-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,071.00 | transaction_form_type: 4 | Footnotes: F1
- Sold 4,071 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 69,218.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
Footnotes:
- F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested.